Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CCR1 | P32246 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.46 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4496289 | 0.91 | PTGDR2 (0.55) | MAPTMAPK1CCR1CCR2HTR2A | |
| SCHEMBL13816300 | 0.79 | PTGDR2 (0.67) | MAPTMAPK1PTGDR2 | |
| SCHEMBL4509606 | 0.77 | MAPT (0.50) | MAPTMAPK1KDM4ESLC6A4PTGDR2 | |
| SCHEMBL13816298 | 0.76 | PTGDR2 (0.59) | MAPK1CCR1CCR2PTGDR2TRIM24 | |
| SCHEMBL4507793 | 0.76 | L3MBTL1 (0.64) | MAPTMAPK1KDM4EHTR2ASLC6A4 | |
| SCHEMBL4517861 | 0.74 | MAPT (0.55) | MAPTMAPK1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1450639 | 0.74 | FFAR4 (0.57) | MAPTKDM4ELMNASMN1; SMN2 | |
| SCHEMBL2693160 | 0.73 | ALDH1A1 (0.63) | MAPTKDM4ELMNASMN1; SMN2EGFR | |
| SCHEMBL4492986 | 0.73 | PTGDR2 (0.74) | CCR1CCR2PTGDR2 | |
| SCHEMBL5665407 | 0.72 | CCR2 (0.79) | MAPTCCR1CCR2KDM4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585511-B1 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541383-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-20080085891-A1 | Asthma and allergic inflammation modulators | FU ZICE | 2008-04-10 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7321001-B2 | Asthma and allergic inflammation modulators | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1585511-A4 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | AMGEN INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1585511-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | Tularik, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | AMGEN INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2004058164-A2 | ASTHMA AND ALLERGIC INFLAMMATION MODULATORS | TULARIK, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085891-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | MAPT 1718/4885MAPK1 1615/4885CCR1 22/4885 |
| US-20040220237-A1 | Asthma and allergic inflammation modulators | IL5, TSLP, CYSLTR2 | MAPT 1718/4885MAPK1 1615/4885CCR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.